Showing results (3261-3270 of 3,662) with videos related to

Sort By:
Pageof 367
Breast (Edinburgh, Scotland)|April 17, 2025
Socioeconomic disparities and osteoarthritis impact hormone therapy adherence in breast cancerB S Jang, J H Chang, K H Shin
Breast (Edinburgh, Scotland)|April 17, 2025
Climate change impacts and sustainability integration among breast international group membersSeamus O'Reilly, Jessica Griffiths, Lisa Fox, et al.
Breast (Edinburgh, Scotland)|April 17, 2025
Analysis of factors influencing chemotherapy-induced peripheral neuropathy in breast cancer patients using a random forest modelHuiqian Xu, Hong Li, Yijing Fan, et al.
Breast (Edinburgh, Scotland)|May 10, 2025
Phyllodes tumors of the breast: Real world data from a multi-institution cohortCarl Sars, Jan Frisell, Paul W Dickman, et al.
Breast (Edinburgh, Scotland)|May 10, 2025
Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter studyUna Kjällquist, Nikos Tsiknakis, Balazs Acs, et al.
Breast (Edinburgh, Scotland)|May 9, 2025
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologistsHope S Rugo, Aditya Bardia, William J Gradishar, et al.
Breast (Edinburgh, Scotland)|May 7, 2025
Impact of routine FDG-PET/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapyJetske L B Gunster, A Marjolein Schrijver, Frederieke H van Duijnhoven, et al.
Breast (Edinburgh, Scotland)|March 29, 2025
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancerJoyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, et al.
Breast (Edinburgh, Scotland)|November 16, 2025
Breaking down the costs for breast cancer: Insights from Sweden's national quality registerXiaoyang Du, Leo Gkekos, Balram Rai, et al.
Breast (Edinburgh, Scotland)|November 12, 2025
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancerAmandine Billaud, Gisella Figlioli, Clémence Mooser, et al.
Pageof 367